论文部分内容阅读
[目的]分析丘脑胶质瘤病例综合治疗的治疗结果。[方法]2009年6月至2011年12月收治病理确诊的丘脑胶质瘤患者31例,接受手术近全切除10例,部分切除14例,活检术7例。术后调强放射治疗8例,三维适形放射治疗23例;1.8~2.0Gy/次,总剂量48.6~60.0Gy(中位剂量54Gy)。放疗期间同步口服替莫唑胺化疗20例。中位随访35.4个月。[结果]全组患者中位生存时间20.6个月,1、2、3年总生存率分别为74.2%、45.2%和36.2%。多因素分析显示WHO分级低、放疗同步化疗的患者预后较好。[结论]WHO分级和放疗期间同步替莫唑胺化疗是影响丘脑胶质瘤预后的主要因素,手术在丘脑胶质瘤治疗中的地位有待进一步研究。
[Objective] To analyze the results of comprehensive treatment of thalamic glioma cases. [Method] Thirty-one patients with pathologically diagnosed thalamic gliomas were admitted to our hospital from June 2009 to December 2011. Ten patients underwent total resection, partial resection in 14 and biopsy in 7 patients. Postoperative IMRT in 8 cases, three-dimensional conformal radiotherapy in 23 cases; 1.8 ~ 2.0Gy / time, the total dose of 48.6 ~ 60.0Gy (median dose of 54Gy). Twenty patients were treated with temozolomide simultaneously during radiotherapy. The median follow-up of 35.4 months. [Results] The median survival time of all patients was 20.6 months. The overall survival rates at 1, 2 and 3 years were 74.2%, 45.2% and 36.2%, respectively. Multivariate analysis showed that WHO patients with low grade, radiotherapy and concurrent chemotherapy in patients with good prognosis. [Conclusions] Synchronized temozolomide chemotherapy is the main factor affecting the prognosis of thalamic gliomas during WHO classification and radiotherapy. The status of surgery in treating glioma remains to be further studied.